Serum concentrations of cross-linked N-telopeptides of type I collagen: New marker for bone resorption in hemodialysis patients

Clinical Chemistry

Volumn 51, Issue 12, 2005, Pages 2312-2317

  Maeno, Yoshifumi ^b   Inaba, Masaaki ^a   Okuno, Senji ^b   Yamakawa, Tomoyuki ^b   Ishimura, Eiji ^a   Nishizawa, Yoshiki ^a  

^a OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b Shirasagi Hospital   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE BONE ISOENZYME; AMINO TERMINAL TELOPEPTIDE; BIOLOGICAL MARKER; DEOXYPYRIDINOLINE; OSTEOCALCIN; PYRIDINOLINE;

ADULT; AGED; ANURIA; ARTICLE; ASSAY; BONE DENSITY; BONE TURNOVER; CORRELATION ANALYSIS; DISEASE MARKER; DUAL ENERGY X RAY ABSORPTIOMETRY; HEMODIALYSIS; HUMAN; MAJOR CLINICAL STUDY; MALE; OSSIFICATION; OSTEOLYSIS; PROTEIN CROSS LINKING; RADIUS; RELIABILITY; RENAL OSTEODYSTROPHY; SENSITIVITY AND SPECIFICITY;

ADULT; AGED; BIOLOGICAL MARKERS; BONE RESORPTION; COLLAGEN; COLLAGEN TYPE I; HUMANS; MIDDLE AGED; PEPTIDES; RENAL DIALYSIS; SENSITIVITY AND SPECIFICITY;

EID: 28044438380     PISSN: 00099147     EISSN: None     Source Type: Journal    
DOI: 10.1373/clinchem.2005.051524     Document Type: Article

References (39)

1. Piraino B, Chen T, Cooperstein L, Segre G, Puschett J. Fractures and vertebral bone mineral density in patients with renal osteodystrophy. Clin Nephrol 1988;30:57-62.
2. Akesson K, Vergnaud P, Gineyts E, Delmas PD, Obrant K. Impairment of bone turnover in elderly women with hip fracture. Calcif Tissue Int 1993;53:162-9.
3. Melton LJ III, Khosla S, Atkinson EJ, O'Fallon WM, Riggs BL. Relationship of bone turnover to bone density and fractures. J Bone Miner Res 1997;12:1083-91.
4. Garnero P, Sornay-Rendu E, Duboeuf F, Delmas PD. Markers of bone turnover predict postmenopausal forearm bone loss over 4 years: the OFELY study. J Bone Miner Res 1999;14:1614-21.
5. Delmas PD, Eastell R, Garnero P, Seibel MJ, Stepan J. The use of biochemical markers of bone turnover in osteoporosis. Osteoporos Int 2000;11(Suppl 6):S2-17.
6. Nishizawa Y, Nakamura T, Ohata H, Kushida K, Gorai I, Shiraki M, et al. Guidelines on the use of biochemical markers of bone turnover in osteoporosis (2001). J Bone Miner Metab 2001;19:338-44.
7. Chiaki O, Yoshikata I, Kikuchi R, Nakayama M, Uchiyama Y, Hirahara, et all. The predictive value of biochemical markers of bone turnover for bone mineral density in postmenopausal Japanese women. J Bone Miner Res 2000;8:1537-44.
8. Okuno S, Inaba M, Kitatani K, Ishimura E, Yamakawa T, Nishizawa Y. Serum levels of C-terminal telopeptide of type I collagen: a useful new marker of cortical bone loss in hemodialysis patients. Osteoporos Int 2005;16:501-9.
9. Okabe R, Nakatsuka K, Inaba M, Miki T, Naka H, Masaki H, et al. Clinical evaluation of the Elecsys β-CrossLaps serum assay, a new assay that measures serum concentrations of bone-derived degradation products of type I collagen C-telopeptides. Clin Chem 2001;47:1410-4.
10. Fledelius C, Johnsen AH, Cloos PA, Bonde M, Quist P. Characterization of urinary degradation products derived from type I collagen. Identification of a β-isomerized Asp-Gly sequence within the C-terminal telopeptide (β1) region. J Biol Chem 1997;272:9755-63.
11. Bonde M, Qvist P, Fledelius C, Riis BJ, Christiansen C. Applications of an enzyme immunoassay for a new marker of bone resorption (CrossLaps): follow-up on hormone replacement therapy and osteoporosis risk assessment. J Clin Endocrinol Metab 1995;80:864-8.
12. Ebeling PR. Potential candidates for bone turnover markers-N-telopeptide cross-kinks of type I collagen (NTX). In: Eastell R, Baumann M, Hoyle NR, Wieczorek L, eds. Bone markers: biochemical and clinical perspectives. London: Martin Dunitz, 2001:27-38.
13. Kumeda Y, Inaba M, Tahara H, Kurioka Y, Isikawa T, Morii H, et al. Persistent increase in bone turnover in Graves' patients with subclinical hyperthyroidism. J Clin Endocrinol Metab 2000;85:4157-61.
14. Inaba M, Nishizawa Y, Mita K, Kumeda Y, Emoto M, Kawagishi T, et al. Poor glycemic control impairs the response of biochemical parameters of bone formation and resorption to exogenous 1,25-dihydroxyvitamin D3 in patients with type 2 diabetes. Osteoporosis Int 1999;9:525-31.
15. Inaba M, Terada M, Nishizawa Y, Shioi A, Ishimura E, Otani S, et al. Protective effect of an aldose reductase inhibitor against bone loss in galactose-fed rats: possible involvement of the polyol pathway in bone metabolism. Metabolism 1999;48:904-9.
16. Lepage R, Roy L, Brossard JH, Rousseau L, Dorais C, Lazure C, et al. A non-(1-84) circulating parathyroid hormone (PTH) fragment interferes significantly with intact PTH commercial assay measurements in uremic samples. Clin Chem 1998;44:805-9.
17. Arnaud CD, Pun KK. Metabolism and assay of parathyroid hormone. In: Coe FL, Favus MJ, eds. Disorders of bone and mineral metabolism. New York: Raven Press, 1992:107-22.
18. Gertz BJ, Clemens JD, Holland SD, Yuan W, Greenspan S. Application of a new serum assay for type I collagen crosslinked N-telopeptides: assessment of clinical changes in bone turnover with and without alendronate treatment. Calcif Tissue Int 1998;63:102-6.
19. Clemems JD, Herrick MV, Singer FR, Eyre DR. Evidence that serum NTx (collagen-type I N-telopeptides) can act as an immunochemical marker of bone resorption. Clin Chem 1997;43:2058-63.
20. Furumitsu Y, Inaba M, Yukioka K, Yukioka M, Kumeda Y, Azuma Y, et al. Levels of serum and synovial fluid pyridinium crosslinks in patients with rheumatoid arthritis. J Rheumatol 2000;27:64-70.
21. Niwa T, Shiobara K, Hamada T, Miyazaki T, Tsukushi S, Uema K, et al. Serum pyridinolines as specific markers of bone resorption in hemodialyzed patients. Clin Chim Acta 1995;235:33-40.
22. Gomes B Jr, Ardakani S, Ju J, Jenkins D, Cerelli MJ, Daniloff YD, et al. Monoclonal antibody assay for measuring bone-specific alkaline phosphatase activity in serum. Clin Chem 1995;41:1560-6.
23. Takahashi M, Kushida K, Nagano A, Inoue T. Comparison of the analytical and clinical performance characteristics of an N-MID versus an intact osteocalcin immunoradiometric assay. Clin Chim Acta 2000;294:67-76.
24. Yoshimura N, Nakatsuka K, Saitoh S, Nishizawa Y, Uchiyama M, Miura M. Serum cross-linked N-telopeptide of type I collagen (NTX) and serum amino-terminal propeptide of type I procollagen (PINP) in residents of a rural community in Japan: reference values classified by age and sex. Osteoporos Jpn 2002;3:171-6.
25. Pagani F, Bonetti G, Stefini F, Panteghini M. Evaluation of a fully automated assay to measure C-telopeptide of type I collagen in serum. Clin Chem Lab Med 2000;38:1111-3.
26. Yamaguchi T, Kanno E, Tsubota J, Shiomi T, Nakai M, Hattori S. Retrospective study on the usefulness of radius and lumbar bone density in the separation of HD patients with fractures from those without fractures. Bone 1996;19:549-55.
27. Stein MS, Packham DK, Ebeling PR, Wark JD, Becker GJ. Prevalence and risk factors for osteopenia in dialysis patients. Am J Kidney Dis 1996;28:515-22.
28. Miki T, Morita A, Nakatsuka K, Tabata T, Inoue T, Nishizawa Y, et al. Changes in bone mineral density in patients on HD due to chronic glomerulonephritis. Osteoporos Int 1997;7(Suppl 3):S193-6.
29. Lindergard B, Cederholm B. Long-time follow-up (10-22 years) of bone mineral density in patients on uninterrupted HD for more than 10 years. Bone Miner 1994;25(Suppl 2):S38.
30. Bilezikian JP, Brandi ML, Rubin M, Silverberg SJ. Primary hyperparathyroidism: new concepts in clinical, densitometric and biochemical features. J Intern Med 2005;1:6-17.
31. Colwell A, Eastell R. The renal clearance of free and conjugated pyridinium cross-links of collagen. J Bone Miner Res 1996;11: 1976-80.
32. Inaba M, Nagasue K, Okuno S, Ueda M, Kumeda Y, Imanishi Y, et al. Impaired secretion of parathyroid hormone, but not refractoriness of osteoblast, is a major mechanism of low bone turnover in hemodialyzed patients with diabetes mellitus. Am J Kidney Dis 2002;39:1261-9.
33. Ueda M, Inaba M, Okuno S, Nagasue K, Kitatani K, Ishimura E et al. Clinical usefulness of the serum N-terminal propeptide of type I collagen as a marker of bone formation in hemodialysis patients. Am J Kidney Dis 2002;40:802-9.
34. Urena P, Ferreira A, Kung VT, Morieux C, Simon P, Ang KS, et al. Serum pyridinoline as a specific marker of collagen breakdown and bone metabolism in HD patients. J Bone Miner Res 1995;10:932-9.
35. Mazzaferro S, Pasquali M, Ballanti P, Bonucci E, Costantini S, Chicca S, et al. Diagnostic value of serum peptides of collagen synthesis and degradation in dialysis renal osteodystrophy. Nephrol Dial Transplant 1995;10:52-8.
36. Apone S, Lee MY, Eyre DR. Osteoclasts generate cross-linked collage N-telopeptides (NTx) but not free pyridinolines when cultured on human bone. Bone 1997;21:129-36.
37. Rosen HM, Moses AC, Garber J, Iloputaife ID, Ross DS, Lee SL, et al. Serum CTX: a new marker of bone resorption that shows treatment effect more often than other markers because of low coefficient of variability and large changes with bisphosphonate therapy. Calcif Tissue Int 2000;66:100-3.
38. Ross PD, Knowlton W. Rapid bone loss is associated with increased levels of biochemical markers. J Bone Miner Res 1998;13:297-302.
39. Dresner-Pollak R, Parker RA, Poku M, Thompson J, Seibel MJ, Greenspan SL. Biochemical markers of bone turnover reflect femoral bone loss in elderly women. Calcif Tissue Int 1996;59:328-33.